Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.

Zatovicova, M; Jelenska, L; Hulikova, A; Csaderova, L; Ditte, Z; Ditte, P; Goliasova, T; Pastorek, J; Pastorekova, S

Zatovicova, M; Jelenska, L; Hulikova, A; Csaderova, L; Ditte, Z; Ditte, P; Goliasova, T; Pastorek, J; Pastorekova, S.

Affiliation

Zatovicova M; Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, Slovak Republic.

Curr Pharm Des ; 16(29): 3255-63, 2010.

Article in En | MEDLINE | ID: mdl-20819068

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antigens, Neoplasm/immunology; Antineoplastic Agents/therapeutic use; Carbonic Anhydrase Inhibitors/therapeutic use; Carbonic Anhydrases/immunology; Catalytic Domain/immunology; Colorectal Neoplasms/drug therapy; Molecular Targeted Therapy/methods; Animals; Antineoplastic Agents/pharmacology; Carbonic Anhydrase IX; Carbonic Anhydrase Inhibitors/pharmacology; Humans; Xenograft Model Antitumor Assays/methods

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Carbonic Anhydrase Inhibitors / Colorectal Neoplasms / Carbonic Anhydrases / Catalytic Domain / Molecular Targeted Therapy / Antibodies, Monoclonal / Antigens, Neoplasm / Antineoplastic Agents Type of study: Evaluation_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Curr Pharm Des Journal subject: FARMACIA Year: 2010 Type: Article

Search on Google

XML

PubMed Links